A live attenuated Listeria monocytogenes vaccine vector expressing SIV Gag is safe and immunogenic in macaques and can be administered repeatedly

Vaccine

Volumn 29, Issue 3, 2011, Pages 476-486

  Sciaranghella, Gaia ^a,b   Lakhashe, Samir K ^a,b   Ayash Rashkovsky, Mila ^a,b   Mirshahidi, Saied ^a,b   Siddappa, Nagadenahalli B ^a,b   Novembre, Francis J ^c   Velu, Vijayakumar ^c,d   Amara, Rama Rao ^c,d   Zhou, Chenghui ^e   Li, Sufen ^e   Li, Zhongxia ^e   Frankel, Fred R ^e   Ruprecht, Ruth M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c EMORY UNIVERSITY   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anti vector immunity; Cellular immune responses; HIV AIDS vaccine; Live attenuated Listeria monocytogenes; Live oral vaccine

Indexed keywords

BACTERIAL VECTOR; GAG PROTEIN; LISTERIA MONOCYTOGENES VACCINE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG SAFETY; EXPRESSION VECTOR; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; LISTERIA MONOCYTOGENES; MACACA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ANIMALS; DRUG CARRIERS; GENE PRODUCTS, GAG; GENETIC VECTORS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; LISTERIA MONOCYTOGENES; MACACA MULATTA; SAIDS VACCINES; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VACCINES, ATTENUATED;

EID: 78650518250     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.072     Document Type: Article

References (59)

1. Baba T.W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000, 6(February (2)):200-206.
2. Mascola J.R., Lewis M.G., Stiegler G., Harris D., VanCott T.C., Hayes D., et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999, 73(May (5)):4009-4018.
3. Parren P.W., Marx P.A., Hessell A.J., Luckay A., Harouse J., Cheng-Mayer C., et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001, 75(September (17)):8340-8347.
4. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000, 6(February (2)):207-210.
5. Wilson N.A., Keele B.F., Reed J.S., Piaskowski S.M., MacNair C.E., Bett A.J., et al. Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol 2009, 83(July (13)):6508-6521.
6. Liu J., O'Brien K.L., Lynch D.M., Simmons N.L., La Porte A., Riggs A.M., et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009, 457(January (7225)):87-91.
7. Hansen S.G., Vieville C., Whizin N., Coyne-Johnson L., Siess D.C., Drummond D.D., et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009, 15(March (3)):293-299.
8. Stover C.K., de la Cruz V.F., Fuerst T.R., Burlein J.E., Benson L.A., Bennett L.T., et al. New use of BCG for recombinant vaccines. Nature 1991, 351(June (6326)):456-460.
9. Weiss S. Transfer of eukaryotic expression plasmids to mammalian hosts by attenuated Salmonella spp. Int J Med Microbiol 2003, 293(April (1)):95-106.
10. + T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env. J Virol 2006, 80(February (4)):1645-1652.
11. Brockstedt D.G., Giedlin M.A., Leong M.L., Bahjat K.S., Gao Y., Luckett W., et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A 2004, 101(September (38)):13832-13837.
12. Jensen E.R., Selvakumar R., Shen H., Ahmed R., Wettstein F.O., Miller J.F. Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA. J Virol 1997, 71(November (11)):8467-8474.
13. Souders N.C., Verch T., Paterson Y. In vivo bactofection: listeria can function as a DNA-cancer vaccine. DNA Cell Biol 2006, 25(March (3)):142-151.
14. Singh R., Paterson Y. Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapy. Expert Rev Vaccines 2006, 5(August (4)):541-552.
15. Wallecha A., Maciag P.C., Rivera S., Paterson Y., Shahabi V. Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy. Clin Vaccine Immunol 2009, 16(January (1)):96-103.
16. Shahabi V., Reyes-Reyes M., Wallecha A., Rivera S., Paterson Y., Maciag P. Development of a Listeria monocytogenes based vaccine against prostate cancer. Cancer Immunol Immunother 2008, 57(September (9)):1301-1313.
17. Peng X., Hussain S.F., Paterson Y. The ability of two Listeria monocytogenes vaccines targeting human papillomavirus-16 E7 to induce an antitumor response correlates with myeloid dendritic cell function. J Immunol 2004, 172(May (10)):6030-6038.
18. Sewell D.A., Pan Z.K., Paterson Y. Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine 2008, 26(September (41)):5315-5320.
19. Wood L.M., Guirnalda P.D., Seavey M.M., Paterson Y. Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors. Immunol Res 2008, 42(1-3):233-245.
20. Tangney M., Gahan C.G. Listeria monocytogenes as a vector for anti-cancer therapies. Curr Gene Ther 2010, 10(February (1)):46-55.
21. Maciag P.C., Radulovic S., Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 2009, 27(June (30)):3975-3983.
22. Lieberman J., Frankel F.R. Engineered Listeria monocytogenes as an AIDS vaccine. Vaccine 2002, 20(May (15)):2007-2010.
23. Frankel F.R., Hegde S., Lieberman J., Paterson Y. Induction of cell-mediated immune responses to human immunodeficiency virus type 1 Gag protein by using Listeria monocytogenes as a live vaccine vector. J Immunol 1995, 155(November (10)):4775-4782.
24. + T cells in the spleen and gut-associated lymphoid tissue by parenteral or mucosal immunization with recombinant Listeria monocytogenes HIV Gag. J Immunol 2003, 170(May (10)):5176-5187.
25. Zhao X., Zhang M., Li Z., Frankel F.R. Vaginal protection and immunity after oral immunization of mice with a novel vaccine strain of Listeria monocytogenes expressing human immunodeficiency virus type 1 gag. J Virol 2006, 80(September (18)):8880-8890.
26. Jiang S., Rasmussen R.A., Nolan K.M., Frankel F.R., Lieberman J., McClure H.M., et al. Live attenuated Listeria monocytogenes expressing HIV Gag: immunogenicity in rhesus monkeys. Vaccine 2007, 25(October (42)):7470-7479.
27. Li Z., Zhang M., Zhou C., Zhao X., Iijima N., Frankel F.R. Novel vaccination protocol with two live mucosal vectors elicits strong cell-mediated immunity in the vagina and protects against vaginal virus challenge. J Immunol 2008, 180(February (4)):2504-2513.
28. Rayevskaya M.V., Frankel F.R. Systemic immunity and mucosal immunity are induced against human immunodeficiency virus Gag protein in mice by a new hyperattenuated strain of Listeria monocytogenes. J Virol 2001, 75(March (6)):2786-2791.
29. Wallecha A., Carroll K.D., Maciag P.C., Rivera S., Shahabi V., Paterson Y. Multiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunotherapeutics. Adv Appl Microbiol 2009, 66:1-27.
30. Paterson Y., Maciag P.C. Listeria-based vaccines for cancer treatment. Curr Opin Mol Ther 2005, 7(October (5)):454-460.
31. Birmingham C.L., Canadien V., Kaniuk N.A., Steinberg B.E., Higgins D.E., Brumell J.H. Listeriolysin O allows Listeria monocytogenes replication in macrophage vacuoles. Nature 2008, 451(January (7176)):350-354.
32. Brzoza K.L., Rockel A.B., Hiltbold E.M. Cytoplasmic entry of Listeria monocytogenes enhances dendritic cell maturation and T cell differentiation and function. J Immunol 2004, 173(August (4)):2641-2651.
33. Webster P. Early intracellular events during internalization of Listeria monocytogenes by J774 cells. J Histochem Cytochem 2002, 50(April (4)):503-518.
34. Cossart P., Toledo-Arana A. Listeria monocytogenes, a unique model in infection biology: an overview. Microbes Infect 2008, 10(July (9)):1041-1050.
35. Lecuit M. Understanding how Listeria monocytogenes targets and crosses host barriers. Clin Microbiol Infect 2005, 11(June (6)):430-436.
36. Ireton K. Entry of the bacterial pathogen Listeria monocytogenes into mammalian cells. Cell Microbiol 2007, 9(June (6)):1365-1375.
37. Drevets D.A., Bronze M.S. Listeria monocytogenes: epidemiology, human disease, and mechanisms of brain invasion. FEMS Immunol Med Microbiol 2008, 53(July (2)):151-165.
38. Williams D., Castleman J., Lee C.C., Mote B., Smith M.A. Risk of fetal mortality after exposure to Listeria monocytogenes based on dose-response data from pregnant guinea pigs and primates. Risk Anal 2009, 29(November (11)):1495-1505.
39. Swaminathan B., Gerner-Smidt P. The epidemiology of human listeriosis. Microbes Infect 2007, 9(August (10)):1236-1243.
40. Brockstedt D.G., Bahjat K.S., Giedlin M.A., Liu W., Leong M., Luckett W., et al. Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat Med 2005, 11(August (8)):853-860.
41. Rudnicka W., Kaczmarek M., Szeliga J., Germann T., Wieckowska M., Rozalska B. The host response to Listeria monocytogenes mutants defective in genes encoding phospholipases C (plcA, plcB) and actin assembly (actA). Microbiol Immunol 1997, 41(11):847-853.
42. Stevens R., Lavoy A., Nordone S., Burkhard M., Dean G.A. Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine. Vaccine 2005, 23(February (12)):1479-1490.
43. Leong M.L., Hampl J., Liu W., Mathur S., Bahjat K.S., Luckett W., et al. Impact of preexisting vector-specific immunity on vaccine potency: characterization of Listeria monocytogenes-specific humoral and cellular immunity in humans and modeling studies using recombinant vaccines in mice. Infect Immun 2009, 77(September (9)):3958-3968.
44. Starks H., Bruhn K.W., Shen H., Barry R.A., Dubensky T.W., Brockstedt D., et al. Listeria monocytogenes as a vaccine vector: virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy. J Immunol 2004, 173(July (1)):420-427.
45. Thompson R.J., Bouwer H.G., Portnoy D.A., Frankel F.R. Pathogenicity and immunogenicity of a Listeria monocytogenes strain that requires d-alanine for growth. Infect Immun 1998, 66(August (8)):3552-3561.
46. Li Z., Zhao X., Zhou C., Gu B., Frankel F.R. A truncated Bacillus subtilis dal gene with a 3' ssrA gene tag regulates the growth and virulence of racemase-deficient Listeria monocytogenes. Microbiology 2006, 152(October (Pt 10)):3091-3102.
47. Siddappa N.B., Song R., Kramer V.G., Chenine A.L., Velu V., Ong H., et al. Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection. J Virol 2009, 83(February (3)):1422-1432.
48. Rasmussen R.A., Ong H., Song R., Chenine A.L., Ayash-Rashkovsky M., Hu S.L., et al. Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges. AIDS 2007, 21(September (14)):1841-1848.
49. Rasmussen R.A., Lakhashe S.K., Ruprecht R.M. Bimodal AIDS vaccine approach: induction of cellular as well as humoral immunity can protect from systemic infection. Vaccine 2010, 28(May (Suppl 2)):B25-31.
50. Dzuris J.L., Sidney J., Appella E., Chesnut R.W., Watkins D.I., Sette A. Conserved MHC class I peptide binding motif between humans and rhesus macaques. J Immunol 2000, 164(January (1)):283-291.
51. Smith M.A., Takeuchi K., Brackett R.E., McClure H.M., Raybourne R.B., Williams K.M., et al. Nonhuman primate model for Listeria monocytogenes-induced stillbirths. Infect Immun 2003, 71(March (3)):1574-1579.
52. Farber J.M., Daley E., Coates F., Beausoleil N., Fournier J. Feeding trials of Listeria monocytogenes with a nonhuman primate model. J Clin Microbiol 1991, 29(November (11)):2606-2608.
53. Cohen P. Immunity's yin and yang. A successful vaccine must first avoid being eliminated by pre-existing immunity before it can promote a protective immune response. IAVI Rep 2006, 10(January-February (1)):1-5.
54. McCoy K., Tatsis N., Korioth-Schmitz B., Lasaro M.O., Hensley S.E., Lin S.W., et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol 2007, 81(June (12)):6594-6604.
55. Lin J., Calcedo R., Vandenberghe L.H., Figueredo J.M., Wilson J.M. Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines. Hum Gene Ther 2008, 19(July (7)):663-669.
56. Vindurampulle C.J., Attridge S.R. Impact of vector priming on the immunogenicity of recombinant Salmonella vaccines. Infect Immun 2003, 71(January (1)):287-297.
57. Gahan M.E., Webster D.E., Wijburg O.L., Wesselingh S.L., Strugnell R.A. Impact of prior immunological exposure on vaccine delivery by Salmonella enterica serovar typhimurium. Vaccine 2008, 26(November (49)):6212-6220.
58. Hage-Chahine C.M., Del Giudice G., Lambert P.H., Pechere J.C. Hemolysin-producing Listeria monocytogenes affects the immune response to T-cell-dependent and T-cell-independent antigens. Infect Immun 1992, 60(April (4)):1415-1421.
59. McClure H.M. Hematologic, blood chemistry, and cerebrospinal fluid data for the rhesus monkey. The rhesus monkey, vol. II, Management, reproduction and pathology, chap. 15 1975, 409-429. Academic Press, San Diego. G.H. Bourne (Ed.).